Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
DN62DG
|
|||
Drug Name |
I3C
|
|||
Synonyms |
Indole-3-carbinol; 700-06-1; 3-Indolemethanol; INDOLE-3-METHANOL; (1H-Indol-3-yl)methanol; 1H-indol-3-ylmethanol; 3-Hydroxymethylindole; 1H-Indole-3-methanol; 3-Indolylcarbinol; Indinol; 3-(Hydroxymethyl)indole; 3-Indole methanol; Indole 3 carbinol; (1H-Indol-3-yl)-methanol; MFCD00005632; UNII-C11E72455F; CHEBI:24814; C11E72455F; NSC-525801; NCGC00090701-06; indol-3-ylmethan-1-ol; I0496; Indole-3-carbinol, 97%; SMR000385784; CCRIS 3261; EINECS 211-836-2; 1H-Indol-3-Yl-Methanol; NSC 525801; BRN 0121323; AI3-60090; 3-Indolecarbinol; 3-Indolylmethanol; Prevention 4 (indole-3-carbinol); indole-3-carbinole; zlchem 356; PubChem7265; 3-hydroxymethyl indole; Spectrum2_001710; Spectrum3_001973; ACMC-209oc7; DSSTox_CID_11458; DSSTox_RID_78876; DSSTox_GSID_31458; BSPBio_003573; MLS001333161; MLS001333162; SCHEMBL195520; SPECTRUM1505320; SPBio_001700; CHEMBL155625; 1H-Indole-3-methanol (9CI); 3-Phenoxybenzylaminehydrochloride; DTXSID7031458; GTPL10047; KBio3_002949; ZLC0198; HMS1789O22; HMS2235E10; HMS3369B02; HMS3651I18; HMS3749E07; ZINC158743; ACN-S002804; ACT03591; BCP00087; HY-N0170; INDOLE-3-CARBINOL (I3C); Tox21_400055; 9344AF; ANW-35813; CCG-38786; HSCI1_000097; NSC525801; s2313; SBB004095; AKOS001075120; AC-7583; CS-7780; DB12881; GS-0916; LS20980; MCULE-6344603304; SB14958; SDCCGMLS-0065970.P001; SDCCGMLS-0065970.P002; VI30396; Indole-3-methanol (Indole-3-carbinol); SMP2_000172; NCGC00090701-01; NCGC00090701-02; NCGC00090701-03; NCGC00090701-04; NCGC00090701-05; NCGC00090701-07; AK-53373; CAS-700-06-1; SY015976; AB0008317; DB-011567; A9256; FT-0615875; ST50308202; SW219849-1; I-2100; M-3233; A836732; SR-01000838318; Q1770257; SR-01000838318-3; BRD-K01815685-001-02-3; BRD-K01815685-001-07-2; Z85923165
Click to Show/Hide
|
|||
Drug Type |
Small molecular drug
|
|||
Indication | Breast cancer [ICD-11: 2C60-2C65; ICD-10: C50, C79.51] | Phase 3 | [1] | |
Structure |
Download2D MOL |
|||
Formula |
C9H9NO
|
|||
Canonical SMILES |
C1=CC=C2C(=C1)C(=CN2)CO
|
|||
InChI |
1S/C9H9NO/c11-6-7-5-10-9-4-2-1-3-8(7)9/h1-5,10-11H,6H2
|
|||
InChIKey |
IVYPNXXAYMYVSP-UHFFFAOYSA-N
|
|||
CAS Number |
CAS 700-06-1
|
|||
PubChem Compound ID | ||||
ChEBI ID |
CHEBI:24814
|
Target and Pathway | Top | |||
---|---|---|---|---|
Target(s) | NF-kappa-B inhibitor alpha (NFKBIA) | Target Info | Inhibitor | [2] |
References | Top | |||
---|---|---|---|---|
REF 1 | ClinicalTrials.gov (NCT02525159) Effectiveness of DIM Supplements to Increase 2-OHE1/16 Ratio (EDIMI216OHE1). U.S. National Institutes of Health. | |||
REF 2 | Protective effect of Indole-3-carbinol, an NF-B inhibitor in experimental paradigm of Parkinson's disease: In silico and in vivo studies. Brain Behav Immun. 2020 Nov;90:108-137. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.